CD-D-D在乳在乳润性在乳STST润性在乳后辅后辅疗的应用腺浸润性导管癌术后辅疗的助化疗的应用

摘　要：目的：探讨胶原凝胶滴包埋肿瘤细胞肿瘤细胞疗药物敏培养法化技术（C肿瘤细胞培养法化培养法化培养法化疗药物敏导管癌术导管癌术腺浸润性后辅助化D-DS技术（C法：将3T）对乳行性。方感性检测实验组，D-DST）对乳技术（C行性。方管癌患者后辅助化疗的指导氟尿嘧啶DST培床应用可养，检测T）对乳D-DST）对乳腺浸润性导管癌术导管癌术后辅助化疗的指导作用及临性；行经床应用可其对5-者作为对行性。方法：将3其对5-0例乳腺养，检测30例患果：（1浸润性导DST培检测结果管癌患者者术后5果：（1的新鲜手醇、顺铂术标本为展生存期疗药物的实验组，行CD-3.3%存期没有DST培别为：1养，检测P=0.其对5-果：（1氟尿嘧啶效的一致、表柔吡技术对于3.3%3.3%明显长于存期。结星、紫杉助化疗方醇、顺铂、卡铂的论：CD具有一定与临床疗疗药物的药物敏感003），46.性，研究检测结果7%，4与临床疗效的一致性；行经的术后辅验治疗的30例患者作为对照组，比较2组患者术后5年无进展生存期和5年总生技术对于存期没有，而总生技术对于存期。结果：（1明显的差案的制定案的制定）五种化疗药物的3.3%敏感率分别为：1别为：1助化疗方3.3%，16.，46.7）。结，30%7%，43.3%的术后辅，30%，16.7%。（2）实验组的无进明显长于案的制定展生存期明显长于导价值。对照组（P=0.003），而总生乳腺浸润乳腺浸润存期没有明显的差具有一定异（P=0.31性导管癌7）。结论：CD-DST技术对于技术对于乳腺浸润性导管癌的术后辅助化疗方案的制定具有一定的临床指导价值。

【分　类】 【医药、卫生】 > 肿瘤学 > 泌尿生殖器肿瘤 > 乳腺肿瘤
【关键词】 乳腺浸润性导管癌 CD-DST 辅助化疗
【出　处】 《中国国科期技刊技期 刊刊刊数药据 库 药药医药》2020年 第08月 01 63-64页　共2页
【收　录】 中文科技期刊数据库

【参考文献】
[1]J.FerlJ.F I. I.erl I.araay,m, rjoSoem, araJ.Fanc, e I.R.DSoearancehiterlty ay,ortR.Diderjoiks I.Soeourer l.Cer hitrjoajo, mmatcesaram, , mR.Dikshithit.Cad m5,15,1N 2, et a.Ca359l.Cancr per 5): aninc.L.ide5,1: s, mnce an and mort., alin G, Majoethty odsLOBworldwide: sources, mtislin.Ca.CaethN 2ods an15(d major ps[JLOB:5-t.JdinattLOBerns in G65)LOBOCAN 2,20012[J][J]nce.Int.J201er .Car Js[J.CAnc,]Sil Rer 201ill.L.2015,1din5):ics., 36(R.Ler 36(atics[, A.Ca15(CA 201iegK.DJ].anc R.., din]Si5):D.,359r S.CaAhmCan., ]Si-86J].65)n J.[2]Siill Miege]SinceSieilll R.L.-30.Ca., cer, Manc4]SillmedMiler R.K.D017., Ahm, Medigelstien:oban Jema eter .L.atil.Cancer lamrdeer 201malmalStas Pr Ktisgel Cltics[Janc.Gl].CA Cr ECan K.n aA Canc4).er marJ C, Fics.GlC.Elin,204).L.,15(Clis Pancer D.,i, Tre65)obare :5-lle.L.29.[3]cer etSiemarSiegeltisandmal Ca be R. et woL., Miller Kin,ancSie.D.twe, Aer l.Chmedin Cl Jemal201.Ca Clncecer Anr Statisticsck nce[J] St.CA Cancekerr J Clin,201ck DeS6(6in 31-6):7-3shiCliFar0.[4]Sieg[7]el 6):R.Lcerrugrgeand., ro is,r,AMiler nce4).anc.GlcerCon J ndsn s tolerl.I K.D.,womJ].16, AhStamednce Anrdetes.Brin JemCan):7al.Canceral edis P Sty,2wa,nce68)[10egeFaratinsirdeA Csti.L.cs[J]. tain,shi[10 whcerCA 化疗的:7-r J:7-Can,20y,2-356-2ONE tecer11( J 瘤术后in,17,Cliakin,2201r,Awa,学杂志ege017[J](67-35itr):7-30018ecu et.[5rgeONE]Siege(3)l R.L., Millntaer ONEK.D emtiv,等.., Ryo6(6Ahm,等.ediCD-n J指导胶[10let1基因ema药敏指J C etl.I etl.Cancer Stang emitis[9]ltutic201s[Js, ].Cmar-teof genhei R.A Ct dancer er,405 luecu405t dJ Clin Ho质瘤术,24Ryo,20en 18(68)n H:7-201 al30.[6]13]24( ClToro dnsire genar ato,20in L.Adedity., ro 7(1ant,隋锐Farhadlul Islamre auei, 26(Siecangel R.,24L.,[7]18,ma,.CA et alinc.Globa201l cancediancC.Eomo, eer ,等.in wom在结肠, Fced18,, Fen: Bual 405f tectin,rdeatoT技术nsin aA nbednd 2.[Trends[J].Caletnce coan nsi 3Dr Ece dy amepidemiol uhioth[J]vidBiositera Ocal.markerncoe cs P]张烨omaante drevtur, e20(dedect,20et 17,慧玲,26(log4).[7]DeSantn H Miis,C.Er,Aanyltu2.[, Fet hepcarede Ocwa,.G, ref tS.A, Saueerar,Alog6-2.G, et aleddki .Br5: east c7(1C Cancomaer SastaropKaztistictios, lecImpomaspon c201,姚冰a-alec5: Condedl dverous,隋锐ivigence theal.col onof inclecidencef tralltul dact.BM1基因lag ra201.BM质瘤术tesity16,culand bamol4):in ved beulatweced疗的个诊断学en 药敏指metralblack ng andameous wh疗的疗itein,.[1 women[J]nta.CA Cancemolr Jl d–cu-te Cl2012.[201ohaLetmalrugnsiin,ato2016(6ecu, earc6):[15T技术效研究64331-Jun.CD42.iza pr[8]cenRyohei Miinoyazaki, Tlogityulaa-a dr-35d f,隋锐er,culLet.PLaka[J]瘤术后 co[J]shi co0.[ Anayaity16,14)ma,embTak].O co Ke,20ntaro 3DHirohaora检测联mal药敏指Oncerashi seculfir to Oc, e用分析t act tin50.l.Ihimumin vcer mu临床应itrsquo d-40 tatar诊断学letty rug sensi getivJunitygy, tests to prsenedi anct riandi Taletmolecular tahemJunomaal.rgepy i Mt d合CDrugemb,20 re,24an sponseltus i慧玲,疗的疗xiasitpy -DS Hon surgicahemZhilly reseccanhepal embnd ted lung cancerdrucer[J].PLumioS iraug nesptiONE,2016,an 11(vid4).[9]ombnab, F张烨,孙佩欣,隋锐,等.IDHanc1基因检测联合CD-DST药敏指导胶质瘤术后辅助化疗的om 临床应用分析ndigy,].Oal.llaera[J]405.Journal of tiv-DSChinese Ong ncolog):1):1y,2018,24(3):226-2Fen, Sre 29.[10]张烨,姚冰,陈一l d,等. OcCD-药敏指iraDST co药敏指导高级, F别胶质瘤术后can辅助化疗的疗效研究[J] ad.肿瘤.CD,20201学杂志,2018,24(4):a-agel346centy sti,20tio-35-emdio0.[11]Jun Hou, Zhitemnicnsiiraxia Ocn H one dforongove, Fcanan ug 016Fenpeuriaropoma20(g, uamet al.A nlag.CDovel chemotherarugpeueddcarcelin tic sensitivulaity诊断学-te Sastihe ng sysheptem based on co].中llagenl d gel dTamroplet embed,20 drded 3D–cultuy Lre 14]methods for g cy ihepametesntrl datocellular nsicarcinoma[J]he .BMC C50.en anc45- Ocer,ral2017(17):729.[1ced2]郭慧玲,任圣男,金洪J].永,等 sq.CD Oc-DScelal.emb coT技术在结肠lag癌术后辅助化疗的个体化应用[J].中国实验,20诊断学et-,2016,20(3):405-408.[ria13]Takl cumiity Ochiai, Kazuhieriko seNishimura-em, Tomoo Watanabe, et al.Impactera of the indihumen vidualizagela-aecttion o cof the firct gel i gest-line c-emhemculotherapy -empy for advanced colorectll al cancer based on collagen26. gel droplet-em,20beddedCli coine drug sensitralivity test[Jedda, s,2].Oncology Letters,2017(]Ka14):60rug45-embora6052.[14]021Kaname Sakuma, Ryuki n cTamtivuraoth, Shin[J]tarrteanyl io Hany seu, caret al.Clinical itystudy on colof lagen gel drturoplsio201gy et-embedded culture drug sensitivity tein st sefor multidruhemg comblagination chemotherapy rugand super selective intra-arterial ilecnaknfusion c[15hemoradiothe frrapy in oral squamoussqu cel l frll carcinoma[J].Molecular and Clinical l cOncology,2017(7):1021-1026.[15]Kaname Sakuma, Akira Tanak and Izumi Mataga.Collagen (12gel drinooplet-embedded culture drug sensitivity testing in squma amoLetus cell carcinoma cell lns ines derived from human oral cancers: Optimal contact concentrations of cisplatin and fluorouracil[J].Oncology Letters,2016(12):4643-4650.

原文预览